Login to Your Account



Gene Therapy Drug Still Alive?

European Commission Breaks With CHMP on AMT's Glybera

By Nuala Moran
Staff Writer

Wednesday, February 1, 2012

LONDON – There's been another twist in the gene therapy saga, with the European Commission refusing to give its usual rubber stamp to the European Medicines Agency's (EMA) decision not to grant marketing authorization to Glybera, a treatment for inherited disorder lipoprotein lipase deficiency (LPL).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription